☆ 4.6 Letter

SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System

LANCET DIABETES & ENDOCRINOLOGY (2017)

Get Full Text
Add to Collection

Journal

LANCET DIABETES & ENDOCRINOLOGY
Volume 5, Issue 9, Pages 680-+

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30257-7

Keywords

-

Categories

Endocrinology & Metabolism

Funding

  1. University of Padova (Padova, Italy)
  2. AstraZeneca
  3. Eli Lilly
  4. Boehringer Ingelheim
  5. Novo Nordisk
  6. Sanofi
  7. Abbott
  8. Novartis
  9. Merck Sharp Dohme
  10. Mediolanum
  11. Servier
  12. Janssen
  13. Merck Sharp Dome
  14. Lilly
  15. Takeda

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.